No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Molecular Guided Therapy Improves Survival for Unfavourable Cancer of Unknown Origin

byAngel GaoandAlisha Yi

August 20, 2024

in StudyGraphics

Reading Time: 1 min read

Click here to read this study in Lancet.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

RELATED REPORTS

The incidence of early-onset metastatic adenocarcinoma may be higher among patients with multiple metastatic sites and peritoneal involvement

Simvastatin (Zocor) in combination with paclitaxel (Taxol) may provide treatment benefit compared to paclitaxel alone for small cell lung cancer

Pfizer’s Talzenna combo significantly delays prostate cancer progression

The Scan by 2 Minute Medicine®: Competition and COVID, Anti-Anaphylaxis, Pulling the Plug on Psychedelics and POTS in the Pool:

RelatedReports

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

Chronic Disease

The incidence of early-onset metastatic adenocarcinoma may be higher among patients with multiple metastatic sites and peritoneal involvement

April 30, 2026

Thoracic radiotherapy improves survival in small-cell lung cancer patients

Chronic Disease

Simvastatin (Zocor) in combination with paclitaxel (Taxol) may provide treatment benefit compared to paclitaxel alone for small cell lung cancer

April 15, 2026

Radiation plus hormone therapy may improve prostate cancer survival

Oncology

Pfizer’s Talzenna combo significantly delays prostate cancer progression

April 9, 2026

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026

#VisualAbstract: Site-Specific Therapy Guided by a 90-Gene Expression Assay Improved Survival in Patients with Cancer of Unknown Primary

Combined MRI and NIH stroke scores may predict stroke prognosis

uniQure: AMT-130 Gene Therapy Slows Progression of Huntington's Disease

#VisualAbstract: Impact of a community health worker led intervention for improved blood pressure control

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result